Floatz logo

Pembrolizumab

Squamous Cell Vulvar Carcinoma

Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Squamous Cell Vulvar Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Christian Hinrichs
Phase 2B
Fludarabine
Christian Hinrichs
Phase 2B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 19 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →